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Abstract 
It is known that fibroblast growth factor-1 (FGF1) lacking a conventional 
signal peptide sequence shows non-classical release independent of the endoplasmic 
reticulum-Golgi system. Recent studies reveal that FGF1 is co-released with S100A13, 
a Ca2+-binding protein that acts as an extracellular cargo molecule. Although both FGF1 
and S100A13 are Cu2+-binding proteins, the role of Cu2+, as well as that of Ca2+, in 
non-classical release, remains to be clarified. In the present study we examined the 
requirements of both metal ions for the interaction between these two proteins. The 
addition of Ca2+ significantly increased the ka value, while decreasing the KD value, for 
the interaction between Strep-tagII-S100A13 and GST-FGF1; both values were 
obtained by use of a quartz crystal microbalance, a real-time mass measuring device. 
The EC50 of Ca2+ to enhance the interaction was 10.11 µM. Although the addition of 
Cu2+ alone had no effect, it caused a marked potentiation of the Ca2+-enhanced 
interaction. The EC50 of Cu2+ for the potentiation was 50.45 nM. On the other hand, the 
EC50 of Ca2+ and the KD value were decreased from 11.69 to 2.07 µM and 0.75 to 0.38 x 
10-7 M, respectively, by the addition of 200 nM Cu2+. The Cu2+–induced potentiation of 
this interaction was abolished by amlexanox, which inhibits non-classical release of 
FGF1. All of these findings suggest that synergistic effects of Ca2+ and Cu2+ play a key 
role in the interaction between FGF1 and S100A13, which is the initial step in 
non-classical release of FGF1. 
 
Keywords: FGF1; S100A13; Non-classical release; Quartz crystal microbalance; 
Amlexanox; Protein-protein interaction. 
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1. Introduction 
 Fibroblast growth factor-1 (FGF1) has a multitude of biological activities. 
During development, FGF1 regulates the induction of neurulation and mesodermal 
induction, and the formation of circulatory and skeletal systems (Friesel and Maciag, 
1999). This protein also plays important roles in neuroprotection, neurogenesis, tissue 
regeneration, angiogenesis, inflammation and the formation of some tumors in 
adulthood  (Friesel and Maciag, 1999; Reuss and von Bohlen und Halbach, 2003). 
Thus, it is evident that FGF1 has a vast number of biological actions. However, the 
molecular machineries underlying the secretion of FGF1 remain to be determined, since 
known endoplasmic reticulum-Golgi-dependent vesicular (or classical) release upon cell 
stimulation is unlikely to be the case with FGF1, which lacks a conventional signal 
peptide sequence at its amino terminus (Cleves, 1997; Nickel, 2003; Prudovsky et al., 
2003). Limited current studies have revealed that the formation of a multi-protein 
complex consisting of FGF1, S100A13 and the p40 form of synaptotagmin-1 is a 
crucial step for stress-induced FGF1 release (Tarantini et al., 1998; LaVallee et al., 
1998; Landriscina et al., 2001b). Recently, we found that S100A13 is co-released with 
FGF1 from brain astrocytes subjected to starvation stress, and this protein behaves as a 
cargo molecule in this stress-induced non-classical FGF1 release (Matsunaga and Ueda, 
2006a). 
 S100A13 belongs to the largest family of Ca2+-binding S100 proteins, having 
an EF-hand peptide sequence (Bhattacharya et al., 2004; Sivaraja et al., 2005). S100 
proteins show cell- and tissue-specific expression throughout the body, and play 
important roles in development, differentiation and tumor formation (Heizmann et al., 
2002; Zimmer et al., 2003). However, S100A13 has some different characteristics from 
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other S100s, as observed in its ubiquitous expression throughout the body (Ridinger et 
al., 2000; Chan et al., 2003). This suggests that S100A13 may have general roles in cell 
signaling. Another characteristic difference is found in its Ca2+-binding sites. Typical 
S100s are present in dimeric form and have four cooperative Ca2+-binding sites, 
whereas monomeric S100A13 has only two Ca2+-binding sites, of different affinity 
(Sivaraja et al., 2005). Recently, we demonstrated that S100A13 plays a role as a cargo 
molecule for Ca2+-dependent non-classical release of FGF1 (Matsunaga and Ueda, 
2006a and b). 
On the other hand, it is reported that dimeric S100A13 also has two 
Cu2+-binding sites with equivalent affinity to the Ca2+-binding sites (Arnesano et al., 
2005; Sivaraja et al., 2006). This unique nature may be related to the fact that S100A13 
has only two Ca2+-binding sites, unlike other S100 family proteins. It should be noted 
that FGF1 also has Cu2+-binding affinity and that the depletion of intracellular Cu2+ by a 
specific chelating agent prevents stress-induced FGF1 release (Landriscina et al., 2001a; 
Matsunaga and Ueda, 2006a and b). Furthermore, it is also reported that the 
homodimerization and non-classical release of FGF1 are closely related to the 
Cu2+-mediated oxidation of cysteine (Cys) 30 (Jackson et al., 1995; Tarantini et al., 
1995). These findings suggest that S100A13 and FGF1 may form a heterooligomer, 
holding Cu2+ inside. 
However, little is known of molecular machinery underlying the Cu2+- and 
Ca2+-mediated regulation of the interaction between FGF1 and S100A13, which is the 
initial step in non-classical release of FGF1. Here, we report a new approach to analyze 
the interplay of Ca2+ and Cu2+ in the FGF1-S100A13 interaction by use of a quartz 
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crystal microbalance (QCM), a real-time mass-measuring biosensor for examining 
protein-protein interactions. 
 6 
2. Experimental Procedures 
2.1. Materials 
Amlexanox was kindly provided by Takeda Pharmaceutical Company 
Limited (Osaka, Japan). 
 
2.2. Expression constructs and purification of recombinant proteins 
The plasmid constructions of rat FGF1 and S100A13, and the purification of 
recombinant proteins have been described previously (Matsunaga and Ueda, 2006a). 
The FGF1 and S100A13 genes were cloned into the pGEX-5X-1 (GE Healthcare 
Bio-Sciences Corp., Piscataway, NJ) and pASK-IBA7 (Genosys Biotechnologies, Inc., 
Woodlands, TX) expression vectors, respectively. Recombinant GST-FGF1 protein was 
purified by Glutathione-SepharoseTM (GE Healthcare Bio-Sciences Corp.). Purified 
GST-FGF1 was confirmed to have equivalent extracellular activity to the native one 
(data not shown). Recombinant Strep-tagII-S100A13 (full-length and ∆88-98) proteins 
were purified using Strep-TactinTM-Sepharose (Genosys Biotechnologies, Inc.). In the 
former recombinant protein, Strep-tagII is the tag peptide, consisting of 8 amino acids. 
In some experiments we used tag-free recombinant proteins, FGF1 and S100A13, 
retaining GIPEF and RDRGPEF as amino terminal residues, respectively by digesting 
GST-FGF1 and Strep-tagII-S100A13 with Factor Xa (Boehringer Mannheim GmbH, 
Mannheim, Germany) for 12 h at 20oC. GST-tag and Strep-tagII were first removed 
using Glutathione-SepharoseTM and Strep-TactinTM-Sepharose, respectively, and Factor 
Xa was then removed by molecular exclusion chromatography using Ultrafree®-MC 
30,000 NMWL centrifugal filter unit (Millipore, Bedford, MA). For the analysis of 
protein-protein interaction and its modulation by ions, we adopted the following 
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molecular weight values (average mass) for GST-FGF1, Strep-tagII-S100A13 
full-length, its ∆88-98 mutant protein, tag-free S100A13, Ca and Cu: 44212.75, 
13840.08, 12490.08, 12055.78, 40.078 and 63.546, respectively. 
 
2.3. Gravimetric measurements with a biosensor quartz crystal microbalance (QCM) 
AT-cut quartz crystals with a fundamental frequency of 27 MHz were 
purchased from Initium Inc. (Tokyo, Japan), and coated with a thin gold surface layer 
(effective surface area, 4.9 mm2). Immediately before use, the gold surface of the quartz 
resonator was cleaned with piranha solution (H2SO4: 30% H2O2=3:1) for 5 min, and 
thoroughly washed with double-distilled water. An anti-GST antibody (GE Healthcare 
Bio-Sciences Corp.) was applied to the resonator for 30 min to obtain a layer for the 
immobilization of GST-FGF1. Next, the resonator was rinsed with interaction buffer 
(50 mM Tris-HCl pH 7.6, 15 mM NaCl, 140 mM KCl), immersed in interaction buffer 
(8 ml), subjected to immobilization of GST-FGF1 for 30 min, and then placed in fresh 
interaction buffer. Protein-protein interactions were detected using an AffinixQ system 
(Initium Inc.), a QCM sensor device. The interactions were determined from the 
frequency changes (oscillation unit, OU: -ΔF in Hz) due to changes in the mass on the 
electrode at the sub-nanogram level, upon application of a small volume (1 – 10 µl) of 
protein solution. From the Sauerbrey formula, an increase of 1 Hz OU is calculated as 
an interaction of a molecule of 30.38 pg with the biosensor. In all immobilization of 
GST-FGF1 on the resonator, it was confirmed that approximately 275 femtomoles of 
GST-FGF1 was immobilized as an absolute amount (an increase in OU of 400 Hz). All 
experiments were carried out at 25 ± 1 °C. All sensorgram data show the OU value 
following the association phase. For equilibrium analysis based on the Langmuir 
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binding model, frequency changes induced by applied protein at any concentration were 
curve-fitted to the linear-reciprocal plot: X/B = [X]/Bmax + KD/Bmax. X and B denote the 
concentration of the added protein and the mass level bound to the immobilized protein, 
respectively. For kinetic analysis, frequency changes induced by cumulatively applied 
protein were curve-fitted to the formula ΔF=A(e(-1/τ)T-1), and the 1/τ value was plotted 
for each concentration of added protein. 1/τ and KD represent ka[X] + kd and kd/ka, 
respectively, where X is the concentration of the added protein. To determine the 
inhibitory activity of amlexanox against FGF1-S100A13 interaction, we calculated 
inhibition constant (Ki value). The τ (relaxation time) value was plotted against each 
concentration of Amlexanox. The Dixon plot gives an intersection point from all 
linear-curves by several concentrations of Strep-tagII-S100A13, and this x-coordinate 
represents - Ki. 
 
2.4. Statistical analysis 
 All results are shown as means + S.E.M. Two-independent groups were compared using 
a Student’s t-test. Multigroups were compared using Dunnett’s multiple comparison test 




3.1. Interaction between FGF1 and S100A13 evaluated by biosensor QCM 
A QCM is a very sensitive mass-measuring device for studying 
protein-protein interactions. To characterize the interaction between FGF1 and 
S100A13, we prepared mutants of both proteins as GST- and Strep-tagII-fusion proteins, 
respectively. Biosensor was first immobilized with GST-FGF1, and immersed in 
interaction buffer containing divalent metal-ions, 500 µM Mg2+, 100 nM Ca2+ and 200 
nM Cu2+ to wait for the stabilization of basal quartz oscillation. When 
Strep-tagII-S100A13 at a concentration of 200 nM was added to the cuvette, the 
reactive oscillation units (OU: -∆F in Hz) were slightly increased, and reached a plateau 
(11 OU) after 5 – 10 min (Fig. 1A). Elevation of Ca2+ rapidly increased the OU in a 
Ca2+ concentration-dependent manner (10 – 100 µM, final concentration), while further 
addition of 2 mM EGTA reversed this increase. Complete reversal was observed in the 
cases with 10 and 30 µM Ca2+. These results suggest the enhancement of interaction 
between GST-FGF1 and Strep-tagII-S100A13 is Ca2+-dependent. 
 We already reported that the Strep-tagII-S100A13 C-terminal deletion mutant (∆88-98) 
shows no interaction with GST-FGF1 in a pull-down assay (Matsunaga and Ueda, 
2006a). The C-terminal 11 amino acids of S100A13 (RKEKVLAIRKK) include six 
basic amino acids (Fig. 1B), a structure that is unique among S100s (Donato, 1999). As 
shown in Fig. 2C, the addition of ∆88-98 mutant to GST-FGF1 showed no significant 




3.2. Reduced interaction of Strep-tagII-S100A13 heterodimer of full-length and 
C-terminal deletion mutant with GST-FGF1 
To characterize the C-terminal region in terms of its interaction with FGF1, the QCM 
assay was performed using a mixture of full-length and C-terminal deletion (∆88-98) 
mutant Strep-tagII-S100A13, in comparison with preparations comprising full-length 
protein. The expected combinations of dimers in the mixture include a homodimer of 
full-length Strep-tagII-S100A13 [F:F], a heterodimer of full-length 
Strep-tagII-S100A13 and its deletion mutant [F:D], and a homodimer of deletion mutant 
[D:D] (Fig. 2A). The application of full-length S100A13 at 100 and 200 nM 
concentration-dependently increased the interaction with GST-FGF1 (275 femtomoles), 
as shown in Fig. 2Ba,b. The addition of deletion mutant (100 and 200 nM) also 
concentration-dependently increased the interaction by full-length protein (100 nM), but 
it was less potent than the full-length (Fig. 2Bd,e). This less potency was confirmed 
when the interaction using equimolar unitable dimers comprised of full-length plus 
mutant was compared to the case with full-length alone. As above-mentioned, the 
expected concentration as unitable dimers in the case with 75 nM full-length plus 75 
nM mutant is the same as in the case with 100 nM full-length. As shown in Fig. 2Ba 
and c, the former combination with mutant showed slightly less potency than the latter 
without mutant. Similar slight change was also observed with 150 nM full-length plus 
150 nM mutant vs. 200 nM full-length (Fig. 2Bb and f). In order to measure the 
stoichiometry of full-length and mutant proteins per GST-FGF1, combinations of these 
proteins at different ratios were adopted (Fig. 2C). The results (OU values) were 
converted to the weight of proteins bound to GST-FGF1, using the fact that an increase 
of 1 OU corresponds to 30.38 pg. In our analysis, we assume that the potency to 
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dimerize is similar among S100A13 species ([F:F], [F:D] and [D:D]) from the fact that 
deletion mutants lacking C-terminal region of other members of S100 protein family 
retain the same potency to dimerize (Osterloh et al., 1998; Donato, 1999). The mixture 
of full-length plus deletion mutant (1:1) comprises 1/3 [F:F], 1/3 [F:D] and 1/3 [D:D], 
as indicated in Fig. 2C. As the [D:D] dimer is unable to interact with GST-FGF1, it was 
not counted toward further analysis (Fig. 2D). The linear curve (double-reciprocal plot) 
from the sample containing full-length protein only represents X/B = [X]/Bmax + 
KD/Bmax (X: concentration of [F:F] and [F:D] dimers). The KD value of [F:F] for 
GST-FGF1 was calculated as 0.915 x 10-7 M from this approximate formula. Plots 
obtained with different concentrations of full-length protein plus deletion mutant (1:1) 
show a slightly upper shifted linear curve, compared to the case with full-length protein 
alone (Fig. 2D). The loss of weight in deletion mutant is only ~10% of the full-length 
S100A13. In addition, as the mixture using this mutant comprises [F:F] and [F:D], the 
calculated loss seems to be only ~2.5% (the ratio of D in this mixture is only 1/4), if the 
affinity to FGF1 is the same between [F:F] and [F:D]. This finding indicates that the 
relative potency of [F:F] to interact with GST-FGF1 is higher than that of [F:D]. 
Assuming that the amount of [F:F] bound to GST-FGF1 is [a], while the amount of 
[F:D] bound to GST-FGF1 is [b], the following formula can be derived: the weight of 
bound S100A13 species = [F:F]MW x [a/(a + b)] + [F:D]MW x [b/(a + b)]. When the 
weight values, 29.55, 34.96, and 38.85 obtained in Fig. 2C were incorporated into the 
formula, the bound ratio ([F:D]/[F:F] = b/a) was calculated as 0.50 + 0.00. Therefore, 
the final estimation of the loss of weight of protein plus deletion mutant (1:1) is 
expected to be only ~1.25% compared to the weight of bound full-length protein alone. 
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3.3. Kinetic analysis of Ca2+-dependent interaction 
To examine the Ca2+-specificity of the enhancement of interaction between 
GST-FGF1 and Strep-tagII-S100A13, Cu2+ and Mg2+ were omitted from the interaction 
buffer. As shown in Fig. 3A, the interaction was enhanced in a Ca2+ 
concentration-dependent manner in the range between 3 and 200 µM, while no more 
enhancement was observed with 500 µM. However, no enhancement was observed with 
200 nM Cu2+ or 500 µM Mg2+. The OU in the presence of various concentrations of 
Ca2+ (3 – 700 µM) showed an equilibration at 10 min. When the OU obtained at 10 min 
(Fig. 3A) was plotted against each Ca2+ concentration, the fitted curve appeared to 
confirm to Michaelis-Menten kinetics (Fig. 3B). In the linear curve by Hanes-Woolf 
plot, the slope denotes 1/ OUmax (Fig. 3C). OUmax and OU50 were 83.33 and 41.67, 
respectively. From the formula indicated in Fig. 3B, the EC50 of Ca2+ for the interaction 
between GST-FGF1 and Strep-tagII-S100A13 was calculated as 10.11 µM. Cumulative 
applications of Strep-tagII-S100A13 showed step-wise increases in OU in the presence 
of 100 µM Ca2+ (Fig. 3D). The plot of 1/τ value against different concentrations of 
Strep-tagII-S100A13 showed a linear curve both in the absence or presence of 100 µM 
Ca2+ (Fig. 3E). From the kinetics, the addition of Ca2+ increased the ka, and decreased 
the KD (Fig. 3F and G).  
 
3.4. Cu2+-induced potentiation of Ca2+-dependent interaction 
To examine the effect of Cu2+ on the interaction, the concentrations of Cu2+ 
were varied in the presence of 100 µM Ca2+ and 500 µM of Mg2+ (Fig. 4A). In the 
absence of Cu2+, the OU value was 68.7 at 10 min, which is equivalent to the value in 
the presence of 100 µM Ca2+ alone. The addition of Cu2+ concentration-dependently 
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potentiated the Ca2+-dependent increase in OU, in the range of 10 – 200 nM. No 
additional increase in OU was induced by 500 nM Cu2+ (data not shown). From the 
kinetics using Cu2+-potentiated OU (∆OU), as mentioned above, the EC50 of Cu2+ to 
potentiate the Ca2+-dependent increase was calculated as 50.45 nM (Fig. 4B and C).  
When the interaction under the condition of various concentrations of Ca2+ was 
analyzed by Michaelis-Menten kinetics and Hanes-Woolf plot, the EC50 was calculated 
as 11.69 µM and 2.07 µM, and the OUmax was 83.33 and 125.00 Hz, in the absence and 
presence of 200 nM Cu2+, respectively (Fig. 4D and E). Kinetic analyses using 
cumulative applications of S100A13 also demonstrated the significant Ca2+ 
concentration-dependent increase in the interaction and synergistic effects by Cu2+ in 
terms of ka and KD (Table 1). Similar results were also observed in the interaction 
between tag-free recombinant proteins. Although the basal activity with tag-free 
proteins showed smaller ka than that with tagged ones in the presence of 100 nM Ca2+ 
alone, the fold-changes in ka by Ca2+ and Cu2+ were comparable between both cases. 
 Repeated experiments revealed that the average + S.E.M. of OU in the 
presence of 100 µM Ca2+, 200 nM Cu2+ and 500 µM of Mg2+, equivalent to OUmax, was 
128.95 + 2.69 Hz (n=4), which corresponds to 3917.50 + 81.71 pg, since 1 Hz OU is 
equivalent to 30.38 pg. On the other hand, the molecular weight of Strep-tagII-S100A13 
holding respectively one and two molecules of Cu2+ and Ca2+ is calculated as 13983.78. 
As the amount of Strep-tagII-S100A13 bound to immobilized GST-FGF1 (275 
femtomoles) on the biosensor was calculated as 280.15 + 5.84 femtomoles, the 
stoichiometry of the interaction between both proteins appears to be 1:1. 
 
3.5. Amlexanox-reversible Cu2+-potentiation 
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As S100A13 protein has been identified as a target of the anti-allergic drug, 
amlexanox, which inhibits degranulation of mast cells and release of FGF1 and 
interleukin-1α (IL-1α) (Mouta Carreira et al., 1998; Shishibori et al., 1999; Mandinova 
et al., 2003), the effects of amlexanox on the interaction between GST-FGF1 and 
Strep-tagII-S100A13 were studied (Table 1). As mentioned above, a Ca2+-dependent 
increase in ka and decrease in KD was observed in the absence of Cu2+. The addition of 
100 µM amlexanox had no effect on these values. The addition of Cu2+ increased ka, 
while decreased KD in the presence of 10-4 M Ca2+, but not in the presence of 10-7 M 
Ca2+. The potentiation by Cu2+ was abolished by the addition of amlexanox. 
This reversal activity of amlexanox in the KD decreased in the presence of 10-4 
M Ca2+, and 200 nM Cu2+ was concentration-dependent in the range of 100 nM to 100 
µM (Fig. 5A). From the Dixon plot, Ki value of amlexanox was calculated as 2.38 + 
0.01 µM (Fig. 5B).  
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4. Discussion 
 Previously, we have successfully demonstrated that S100A13 is a cargo 
molecule for stress-induced non-classical release of FGF1, and that Ca2+ mobilization is 
involved in the interaction between FGF1 and S100A13 and co-release (Matsunaga and 
Ueda, 2006a and b). In the present study, we clarified that Cu2+ is another regulator that 
synergistically potentiates the Ca2+-dependent interaction, an initial step in the 
non-classical release of FGF1, using a biosensor QCM assay. 
 QCM is a real time-mass measuring device to determine the intermolecular 
interaction. The interactions were detected as the change in the intrinsic frequency of 
quartz crystal, due to changes in the mass on the electrode. First we demonstrated the 
Ca2+ concentration–dependency on the interaction between GST-FGF1 and 
Strep-tagII-S100A13, being consistent to the fact that S100A13 possesses EF-hand 
domain for Ca2+-binding. Although Ca2+ alone, but not Mg2+ or Cu2+ alone caused this 
interaction, the EC50 of Ca2+ was as high as 10.11 µM, a concentration, which is not 
normally expected in the cytosol. When 200 nM Cu2+ was added with Ca2+, the EC50 of 
Ca2+ was decreased to 2.07 µM, a concentration, which is expected in the cytosol when 
the cell is stimulated, e.g. through Gq/11-coupled receptor. The involvement of Cu2+ in 
the interaction was supported by our previous study, in which the fluorescence 
resonance energy transfer signal between Venus (YFP)-FGF1 and CFP-S100A13 
expressing in NG108-15 hybrid cells was decreased by tetrathiomolybdate, a Cu2+ 
chelating agent (Matsunaga and Ueda, 2006b). 
Our previous studies demonstrated that the stress-induced release of FGF1 is 
mediated through activation of Ca2+-induced Ca2+ release (CICR) and a 
voltage-dependent N-type Ca2+ channel (Matsunaga and Ueda, 2006a and b). Both 
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mechanisms cause Ca2+ influx and raise the Ca2+ concentration to sub-mM levels at the 
so-called microdomain area in vicinity of plasma membranes or endoplasmic reticulum 
(Schneggenburger and Neher, 2000; Verkhratsky, 2002; Bouchard et al., 2003; Schwarz, 
2003; Tully and Treistman, 2004; García et al., 2006). However, the present fact that the 
addition of Cu2+ decreased the Ca2+ concentration required for the interaction to 
approximately 2 µM Ca2+, suggests that the interaction does not necessarily occur at the 
microdomain area. Therefore the involvement of CICR and N-type Ca2+ channel 
activations in the stress-induced FGF1 release may be related to other unidentified 
mechanisms than the initial interaction between FGF1 and S100A13 (Fig. 6A). 
A recent study using NMR (Arnesano et al., 2005) proposed that the addition of 
Ca2+ causes structural activation of S100A13 homodimer, and creates two protrusions 
of positively charged residues located at the C-terminal end (Fig. 6B), which may 
facilitate the interaction with an acidic protein, such as FGF1. On the other hand, FGF1 
is reported to be homodimerized through the Cu2+–catalyzed oxidation of Cys30 of 
FGF1, and released upon stress in a non-classical manner (Tarantini et al., 1998; 
LaVallee et al., 1998; Landriscina et al., 2001a). Thus, it is interesting to speculate that 
Cu2+ bound to S100A13 may stabilize the interaction between FGF1 and S100A13 
through oxidation and homodimerization of FGF1 (Fig. 6C). 
Amlexanox, an inhibitor of co-release of FGF1 and S100A13, abolished the 
Cu2+-potentiation of the Ca2+–enhanced interaction between both proteins. Although 
this inhibitor has been known to bind to the C-terminus of S100A13 (Mouta Carreira et 
al., 1998; Okada et al., 2002), a recent report demonstrated that it also binds to FGF1, 
particularly to a locus close to Cys30 of this protein (Rajalingam et al., 2005). These 
findings may well explain why amlexanox selectively abolished Cu2+-potentiation, 
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without affecting basal Ca2+–enhancement. These results indicate that amlexanox might 
prevent S100A13 from functioning as a Cu2+-donor to FGF1 (Cys30).  
Thus, it is evident that Cu2+ plays a key role in the regulation of this 
protein-protein interaction. Although the static role of Cu2+ in non-classical FGF1 
release is proven (Tarantini et al., 1998; LaVallee et al., 1998; Landriscina et al., 2001a), 
its dynamic regulation is unlikely to be important, since the cellular level may not 
change upon the stress. However, some genetic diseases are closely related to the 
deficiency or excess of Cu2+. These include Menkes disease and Wilson disease, which 
include neurological symptoms (Strausak et al., 2001; Mercer, 2001). It remains to be 
determined whether these diseases are related to the non-classical release of FGF1 or 
other molecules. However, copper-chelating therapy for cancer patients is well known 
in the clinic (Daniel et al., 2004). In addition, there is a report that tetrathiolmolybdate 
repressed neointimal thickening after vascular injury in the rat, possibly through an 
inhibition of S100A13-dependent non-classical IL-1α release (Mandinov et al., 2003). 
It should be noted that S100A13 expression in brain astrocytes is claimed to be a maker 
of tumor grading and vascularization (Landriscina et al., 2006). 
In the present study, we successfully demonstrated that dimeric S100A13 
interacts with FGF1 and this interaction occurs at a stoichiometry of 1:1. We have 
reported that the Ca2+-dependent interaction requires C-terminal basic region of 
S100A13, since the stress-induced FGF1 release completely disappeared in C6 glioma 
cells expressing S100A13 ∆88-98 mutant (Matsunaga and Ueda, 2006a), suggesting 
that this deletion mutant functions as a potent dominant negative regulator for FGF1 
release. In the present study, however, we demonstrated that [D:D] homodimer has no 
potency to interact with FGF1. Therefore, the formation of [F:D] heterodimer, which 
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still retains 50% of [F:F] homodimer, is presumed to play a major role in the regulation 
of FGF1 release from the cell over-expressed with deletion mutant. However, this fact is 
not enough to explain the complete loss of FGF1 release from the cell expressing 
deletion mutant. Therefore, it may be speculated that the deletion mutant loses the 
potency to interact with unidentified S100A13 target molecules, involved in the 
stress-induced FGF1 release. 
In conclusion, we describe a new approach to studying the role of divalent 
cations in protein-protein interactions, using biosensor QCM. Through this study, it was 
revealed that the synergistic effects of Ca2+ and Cu2+ play a key role in the interaction 
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Fig. 1. Interaction between GST-FGF1 and Strep-tagII-S100A13 or its deletion mutant. 
(A) Ca2+-sensitive interaction between GST-FGF1 and Strep-tagII-S100A13. 
Interactions were evaluated by the change in oscillation units (OU: -∆F in Hz), 
reflecting the change in the mass on the electrode sensor chip, on which GST-FGF1 had 
previously been immobilized. A small increase in OU was observed when 200 nM 
Strep-tagII-S100A13 was added to the interaction buffer in the cuvette at time 0. 
However, a large increase was observed following the addition of 10 – 100 µM Ca2+, 
while this increase was reversed by 2 mM EGTA. Arrow-heads denote application 
points. (B) S100A13 deletion mutant. The ∆88-98 mutant retains two Ca2+-binding 
EF-hand motifs, but lacks the C-terminal basic peptide region. (C) Lack of interaction 
of GST-FGF1 with Strep-tagII-S100A13 Δ88-98 mutant. 
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Fig. 2. Decreased interaction of GST-FGF1 with Strep-tagII-S100A13 heterodimers of 
full-length protein and C-terminal deletion mutant. (A) Three expected dimers 
comprising full-length [F] and Δ88-98 mutant [D]. (B) Evidence for the partial 
interaction activity of Δ88-98 in the presence of full-length Strep-tagII-S100A13. (C) 
Maximum mass level bound to GST-FGF1 in various combinations of full-length 
Strep-tagII-S100A13 [F] and Δ88-98 mutant [D]. An increase by 1 Hz OUmax at 30 min 
is calculated as a molecular mass of 30.38 pg bound to GST-FGF1. Results represent 
means + S.E.M. Numbers indicating gray columns are the weight of bound 
Strep-tagII-S100A13 mutant protein (x 10-1 ng). (D) Equilibrium analysis 
(linear-reciprocal plot) of the interaction of GST-FGF1 and dimeric 
Strep-tagII-S100A13 mutants. All data were derived from triplicate measurements. 
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Fig. 3. Ca2+-enhanced interaction between GST-FGF1 and Strep-tagII-S100A13. (A) 
Time course of the interaction in the presence of various concentrations of Ca2+. No 
significant enhancement of the interaction was observed with 500 µM Mg2+ or 200 nM 
Cu2+. (B) Ca2+-concentration dependent curve. The OU value was determined at 10 min. 
This plot fitted to the logarithmic curve used for Michaelis-Menten kinetics (y = 25.371 
LOG[x] + 16.176). (C) Hanes-Woolf plot. Each data point in (B) was used for this 
kinetic analysis. The linear curve is represented by the following formula, y = 0.012[x] 
+ 0.173. The EC50 (10.11 µM) of Ca2+ for GST-FGF1– Strep-tagII-S100A13 interaction 
was determined by the formula in (B), using OU50 (41.67), which is calculated as 0.5 x 
OUmax (83.33). (D) Cumulative application of Strep-tagII-S100A13 in the presence of 
100 µM Ca2+. Arrow-heads denote application points of Strep-tagII-S100A13 (final 
concentration: 12.5 – 425 nM). (E) Kinetic analysis of the Ca2+ requirement for the 
FGF1-S100A13 interaction. The 1/τ value from the cumulative Strep-tagII-S100A13 
application-induced OU change in (D) was plotted against each concentration (12.5 – 
425 nM) and this plot was fitted to a linear curve. A slope and intercept denote ka and kd, 
respectively. kd/ka represents KD value. (F and G) The ka and KD values for the 
Ca2+-enhanced interaction between GST-FGF1 and Strep-tagII-S100A13. The data 
shown are means + S.E.M. *p < 0.01 vs. none (Student’s t-test). All data were derived 
from triplicate measurements. 
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Fig. 4. Potentiation of the Ca2+-enhanced interaction between GST-FGF1 and 
Strep-tagII-S100A13 by Cu2+. (A) Time course of interaction in the presence of various 
concentrations of Cu2+. Results represent data under the condition of a high 
concentration (100 µM) of Ca2+. (B) Cu2+ concentration-dependent potentiation of the 
interaction. The OU represents the difference between the presence and absence of Cu2+ 
at 10 min. (C) Hanes-Woolf plot. The EC50 of Cu2+ for potentiation was 50.45 nM. (D) 
Ca2+ concentration-response curve for the GST-FGF1 - Strep-tagII-S100A13 interaction 
in the presence or absence of Cu2+. (E) Hanes-Woolf plot. Each data point in (D) was 
used for this kinetic analysis. The EC50 of Ca2+ was 2.07 or 11.69 µM in the presence or 
absence of Cu2+, respectively. All data were derived from triplicate measurements. 
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Fig. 5. Amlexanox-induced inhibition of the interaction between GST-FGF1 and 
Strep-tagII-S100A13. (A) Amlexanox concentration-dependent increase in KD values 
for the interaction. The data shown are means + S.E.M. *p < 0.05 and **p < 0.01 vs. the 
absence of amlexanox (Student’s t-test). (B) Dixon plot. Relaxation time (τ) values 
were plotted against different concentrations of amlexanox (0, 0.1, 1 and 3 µM). 
Linear-curves show an intersection point, and this x-coordinate represents - Ki. Arrow 
denotes an intersection point. Data were derived from triplicate measurements. All 
experiments were analyzed in interaction buffer containing 500 µM Mg2+, 100 µM Ca2+ 
and 200 nM Cu2+. 
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Fig. 6. Ca2+ and Cu2+-involvements of FGF1-S100A13 interaction. (A) FGF1-S100A13 
interaction in the cytosol. Microdomain is the area containing sub-mM levels of Ca2+ in 
the vicinity of membrane voltage-dependent N-type Ca2+ channel and ryanodine 
receptor in the endoplasmic reticulum (ER). The Ca2+ level in the cytosol, where the 
interaction between FGF1 and Cu2+-bound S100A13 is presumed to occur, is below 2 
µM in the activated cell. (B and C) Schematic model for structural interplay between 
Ca2+ and Cu2+ binding in the formation of the FGF1-S100A13 complex. (B) Proposed 
model for the Ca2+-induced conformational change of dimeric S100A13 (Homo 
sapiens). The model represents vertical views of the electrostatic potential surface of 
apo-S100A13 (Protein Data Bank: 1YUS) and Ca2+-S100A13 (1YUU). The negative to 
positive potential charged amino acids are represented in a blue to red gradient color. A 
positively charged cluster was located at the C-terminal end of S100A13 (arrows). (C) 
A hypothetical model for Cu2+-regulated interaction between FGF1 and S100A13. The 
model represents a ribbon representation of the interaction between FGF1 (Homo 
sapiens, Protein Data Bank: 2ERM) and S100A13, and its regulation by Ca2+ and Cu2+. 
The potential Cu2+-binding residues of Ca2+-S100A13 are represented as yellow wires 
(Glu4, Glu8, Glu11 and His48’). In the hypothesis, Ca2+ enhances the interaction 
between FGF1 and S100A13. In the presence of Ca2+, two Cu2+ ions bind to the 
S100A13 dimer, which in turn oxidizes the Cys30 residue of FGF1 as a Cu2+ donor. The 
resulting disulfide bond between two FGF1 molecules may potentiate the 
Ca2+-enhanced interaction between FGF1 and S100A13. Ca2+ and Cu2+ are represented 




Table 1. The association rate constant (ka) and dissociation constant (KD) value of 
S100A13 for FGF1. 
    Ca
2+       
(M) 




4 M-1s-1)   KD (10-7 M)     
  A 10-7 - 0 9.53 + 0.20   5.36 + 0.16     
  B 10-4 - 0 40.3 + 0.49 ** 0.75 + 0.01 **   
  C 10-7 + 0 8.49 + 0.36   4.72 + 0.18     
 D 10-4 + 0 55.0 + 0.56 **## 0.38 + 0.01 **#  
  E 10-7 - 0 1.67 + 0.36   5.19 + 1.16     
  F 10-4 - 0 9.48 + 0.37 ** 0.21 + 0.01 *   
  G 10-4 + 0 15.2 + 0.65 ## 0.13 + 0.01     
  H 10-4 - 100 39.7 + 0.34   0.76 + 0.01     
  I 10-4 + 100 42.9 + 0.51 † 0.71 + 0.01 †   
The interaction between FGF-1 and S100A13 was enhanced by the further addition of 
Ca2+ and potentiated by the addition of Cu2+. A–D and H–I: The interaction was 
analyzed by both GST-FGF1 and Strep-tagII-S100A13. GST-FGF1 was immobilized 
on the anti-GST antibody coated sensor chip, hence orientation of FGF-1 (host sample) 
was fixed. ka and KD were obtained by the analysis using cumulative application of 
recombinant S100A13 protein (guest sample). E–G: The FGF1-S100A13 interaction 
was analyzed by using tag-free recombinant proteins. Tag-free FGF1 was directly 
immobilized on sensor chip. The Cu2+–induced potentiation of this interaction was 
abolished by amlexanox. Each experiment was analyzed in 500 µM MgCl2-containing 
interaction buffer. The data shown are means + S.E.M. *p < 0.05 and **p < 0.01 vs. 
corresponding control (A, C and E). #p < 0.05 and ##p < 0.01 vs. corresponding free of 
Cu2+ (B and F). †p < 0.01 vs. D. All significant differences were analyzed by Dunnett’s 
multiple comparison test. 
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